HF

Hui Feng

Departments of Pharmacology and Medicine, Boston University School of Medicine

Affiliated withBoston University School of MedicineThe Cancer Research Center, Boston University School of Medicine

Research Area

Biography

Trained as a physician and cancer biologist, Dr. Feng has applied the zebrafish as a model to study MYC-driven cancers over seventeen years. Her laboratory at Boston University (www.bu.edu/zgct) utilizes multiple zebrafish models of cancer to gain mechanistic insights into MYC-mediated oncogenic pathways and identify novel therapeutic targets for MYC-driven cancers.

JoVE Journal Publications

ArticleTotal : 2
Year
In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish
Publication title

Cited by 5

2020
2026

Other Publications

Article
Year
BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.

Leukemia| PubMed ID: 24342948

2014
2014
2015
2015
2016
Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights.

Advances in experimental medicine and biology| PubMed ID: 27165361

2016
2017
2017
2017
2018
Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor.

International journal of molecular sciences| PubMed ID: 29735912

2018
2018
2018
2018
2019
2019
2019
2019
Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan.

Molecular cancer research : MCR| PubMed ID: 31932471

2020
2020
2020
2024